Bacillus subtilis-derived peptides disrupt quorum sensing and biofilm assembly in multidrug-resistant Staphylococcus

Kyle R Leistikow1, Daniel S May2,3, Won Se Suh4

  • 1Department of Biological Sciences, Marquette University, Milwaukee, Wisconsin, USA.

Msystems
|July 11, 2024
PubMed

Insights

Researchers discovered a novel probiotic strain, Bacillus subtilis 6D1, that effectively combats multidrug-resistant Staphylococcus aureus biofilms. This strain produces peptides that inhibit biofilm formation and enhance antibiotic effectiveness, offering new therapeutic strategies.

Area of Science:

  • Microbiology and Infectious Diseases
  • Probiotic Therapeutics
  • Antimicrobial Resistance

Background:

  • Multidrug-resistant Staphylococcus aureus poses a significant global health threat due to high morbidity and mortality rates.
  • S. aureus biofilms protect bacteria from antibiotics and facilitate the spread of resistance genes, necessitating novel antibiofilm strategies.
  • Probiotic bacteria, such as Bacillus subtilis, show promise in reducing S. aureus colonization and virulence, but their mechanisms are often unclear.

Purpose of the Study:

  • To identify novel strains and compounds with potent antibiofilm activity against multidrug-resistant S. aureus.
  • To elucidate the mechanisms by which probiotic-derived compounds inhibit S. aureus biofilm formation and enhance antibiotic efficacy.
  • To evaluate the therapeutic potential of identified probiotic strains and their derived compounds in combating S. aureus infections.

Main Methods:

  • Screening of 1,123 environmental Bacillus isolates for antibiofilm activity against S. aureus.
  • Isolation and characterization of active compounds from a potent B. subtilis 6D1 strain using biochemical and molecular networking analysis.
  • Assay of B. subtilis 6D1 peptides' efficacy in inhibiting biofilm formation, disassembling mature biofilms, and improving antibiotic sensitivity in S. aureus models.
  • Evaluation of S. aureus-induced cytotoxicity and cytokine response in HT29 human intestinal cells treated with B. subtilis 6D1 peptides.

Main Results:

  • A single strain, Bacillus subtilis 6D1, demonstrated potent inhibition of S. aureus biofilm growth and disassembly of mature biofilms.
  • B. subtilis 6D1 utilizes Agr quorum sensing interference to reduce S. aureus virulence and enhance antibiotic sensitivity.
  • Active compounds identified as multiple surfactin isoforms and an uncharacterized peptide, with the latter showing superior antibiofilm activity compared to commercial surfactin.
  • B. subtilis 6D1 peptides significantly inhibited biofilm formation across different S. aureus Agr backgrounds and protected human intestinal cells from S. aureus-induced cytotoxicity.

Conclusions:

  • Bacillus subtilis 6D1 is a promising source of novel antibiofilm agents effective against multidrug-resistant S. aureus.
  • Probiotic-derived peptides targeting Agr quorum sensing represent a viable strategy to combat S. aureus infections and overcome antibiotic resistance.
  • Targeted screening of microbial diversity can uncover unique probiotic strains with specific mechanisms for therapeutic applications in clinical and agricultural settings.